REG - Litigation Cap. Mgmt - Australian Regulation of Litigation Funders

Litigation Capital ManagementAnnouncement

26/05/2020 07:01

RNS Number : 8345N
  
Litigation Capital Management Ltd
  
26 May 2020
  
 

26 May 2020
 
Litigation Capital Management Limited
(LCM or the Company)
 
Australian Regulation of Litigation Funders
 
Litigation Capital Management Limited (AIM:LIT), a leading international provider of disputes financing solutions, notes the announcement on 22 May 2020 by the Federal Treasurer of Australia, Josh Frydenberg, that litigation funders operating in Australia will be subject to new regulation requiring them to obtain and maintain an Australian Financial Services License (AFSL).  
 
LCM believes it is the only litigation financier in Australia that currently holds and maintains an AFSL.  Currently the supply of litigation finance is exempt from the requirement to hold an AFSL and such exemption is likely to be removed by August 2020.  This places LCM in an advantageous position against its peers operating in Australia.
 
As part of the new regulatory process, LCM has been asked by the Australian Federal Government to assist in a parliamentary inquiry into whether any further regulation of litigation finance is required in the context of class actions, the findings and recommendations of which will be made public.  LCM has anticipated for some time that class actions in Australia would be the subject of further regulation and expressed its support for such an initiative while assisting in two prior inquiries, one by the Australian Federal Government and one by a State Government.  
 
LCM actively manages its portfolio of investments with its objective of spreading investment risk to ensure that no industry sector or type of claim dominates its portfolio.  Specifically, LCM limits the number of class actions that it is prepared to invest in depending upon the size of its overall portfolio.  LCM remains firmly focussed on the provision of disputes financing solutions in the areas of insolvency, commercial disputes, arbitral disputes and corporate portfolio funding.
 
Patrick Moloney, CEO of LCM, commented: "LCM anticipated changes to regulation and as a result already holds an Australian Financial Services License.  LCM fully supports the move to increase regulation in our industry.  Regulation of litigation funding insofar as it concerns class actions is something that is not only welcomed by LCM but could provide it with a strategic advantage as the cost and compliance issues is likely to create further barriers to entry and restrict the numbers of financiers that can fund class actions."  
 
Enquiries
 



Litigation Capital Management


c/o Alma PR 




Patrick Moloney, Chief Executive Officer


















Canaccord (Nomad and Joint Broker) 


Tel: 020 7523 8000




Bobbie Hilliam


















Investec Bank plc (Joint Broker)


Tel: 020 7597 5970




David Anderson


















Alma PR


Tel: 020 3405 0205




Rebecca Sanders-Hewett


LCM@almapr.co.uk




Justine James








David Ison







 
NOTES TO EDITORS
 
Litigation Capital Management (LCM) is a global provider of disputes finance which operates two business models. The first is direct investments made from LCM's permanent balance sheet capital and the second is fund and/or asset management. Under those two business models, LCM currently pursues three investment strategies: Single-case funding, Corporate portfolio funding and Acquisitions of claims. LCM generates its revenue from both its direct investments and also performance fees through asset management.
LCM has an unparalleled track record, driven by effective project selection, active project management and robust risk management. 
 
Headquartered in Sydney, with offices in London, Singapore, Brisbane and Melbourne, LCM listed on AIM in December 2018, trading under the ticker LIT.
 
www.lcmfinance.com
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
MSCSESESIESSEFI